These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 37036268)
21. Prolonged High-Dose Bivalirudin Infusion Reduces Major Bleeding Without Increasing Stent Thrombosis in Patients Undergoing Primary Percutaneous Coronary Intervention: Novel Insights From an Updated Meta-Analysis. Fahrni G; Wolfrum M; De Maria GL; Banning AP; Benedetto U; Kharbanda RK J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27451466 [TBL] [Abstract][Full Text] [Related]
22. Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial. Goel R; Power D; Tchetche D; Chandiramani R; Guedeney P; Claessen BE; Sartori S; Cao D; Meneveau N; Tron C; Dumonteil N; Widder JD; Hengstenberg C; Ferrari M; Violini R; Stella PR; Jeger R; Anthopoulos P; Deliargyris EN; Mehran R; Dangas GD Int J Cardiol; 2019 Dec; 297():22-29. PubMed ID: 31630816 [TBL] [Abstract][Full Text] [Related]
23. Association between arterial access site and anticoagulation strategy on major bleeding and mortality: A historical cohort analysis in the Veteran population. Bagai J; Little B; Banerjee S Cardiovasc Revasc Med; 2018; 19(1 Pt B):95-101. PubMed ID: 28624360 [TBL] [Abstract][Full Text] [Related]
24. Safety of bivalirudin in patients with coronary artery disease. Abdel-Wahab M; Richardt G Expert Opin Drug Saf; 2012 Jan; 11(1):141-50. PubMed ID: 21999110 [TBL] [Abstract][Full Text] [Related]
25. Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non st-segment elevation myocardial infarction. Leibundgut G; Pache J; Schulz S; Berger PB; Ferenc M; Gick M; Mehilli J; Kastrati A; Neumann FJ J Interv Cardiol; 2013 Dec; 26(6):623-9. PubMed ID: 24118114 [TBL] [Abstract][Full Text] [Related]
26. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143 [TBL] [Abstract][Full Text] [Related]
27. Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial. Geisler T; Droppa M; Gawaz M; Steinhubl SR; Bertrand ME; Lincoff AM; Cequier AR; Desmet W; Rasmussen LH; Hoekstra JW; Bernstein D; Deliargyris EN; Mehran R; Stone GW Catheter Cardiovasc Interv; 2016 Aug; 88(2):174-81. PubMed ID: 26332193 [TBL] [Abstract][Full Text] [Related]
28. Bleeding outcomes after routine transradial primary angioplasty for acute myocardial infarction using eptifibatide and unfractionated heparin: a single-center experience following the HORIZONS-AMI trial. Moody WE; Chue CD; Ludman PF; Chan YK; Narayan G; Millington JM; Townend JN; Doshi SN Catheter Cardiovasc Interv; 2013 Sep; 82(3):E138-47. PubMed ID: 23074143 [TBL] [Abstract][Full Text] [Related]
29. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital. Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538 [TBL] [Abstract][Full Text] [Related]
30. Impact of bivalirudin on in-hospital bleeding and six-month outcomes in octogenarians undergoing percutaneous coronary intervention. Lemesle G; De Labriolle A; Bonello L; Syed A; Collins S; Maluenda G; Torguson R; Kaneshige K; Xue Z; Suddath WO; Satler LF; Kent KM; Lindsay J; Pichard AD; Waksman R Catheter Cardiovasc Interv; 2009 Sep; 74(3):428-35. PubMed ID: 19360860 [TBL] [Abstract][Full Text] [Related]
32. Novel Approaches for Preventing or Limiting Events (NAPLES III) Trial: randomised comparison of bivalirudin versus unfractionated heparin in patients at high risk of bleeding undergoing elective coronary stenting throught the femoral approach. rationale and design. Briguori C; Visconti G; Focaccio A; Donahue M; Golia B; Selvetella L; Ricciarelli B Cardiovasc Drugs Ther; 2014 Jun; 28(3):273-9. PubMed ID: 24781074 [TBL] [Abstract][Full Text] [Related]
33. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III). Waksman R; Bertrand O; Driesman M; Gruberg L; Rossi J; Mehta S; Swymelar S; Dvir D; Xue Z; Torguson R J Interv Cardiol; 2013 Apr; 26(2):107-13. PubMed ID: 23240743 [TBL] [Abstract][Full Text] [Related]
34. Patients treated with bivalirudin are still at higher risk of stent thrombosis: a comprehensive meta-analysis of randomised clinical trials of bivalirudin and heparin for percutaneous coronary interventions. Grajek S; Michalak M; Gwizdała A; Araszkiewicz A; Grygier M; Hiczkiewicz J; Lesiak M Kardiol Pol; 2018; 76(4):740-749. PubMed ID: 29350380 [TBL] [Abstract][Full Text] [Related]
35. Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice. Showkathali R; Davies JR; Parker M; Taggu W; Tang KH; Clesham GJ; Gamma RA; Sayer JW; Aggarwal RK; Kelly PA Cardiovasc Revasc Med; 2013; 14(5):289-93. PubMed ID: 23972537 [TBL] [Abstract][Full Text] [Related]
36. Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse hemorrhagic events by transradial access site and angioX) OCT study. Garcia-Garcia HM; Adamo M; Soud M; Yacob O; Picchi A; Sardella G; Frigoli E; Limbruno U; Rigattieri S; Diletti R; Boccuzzi G; Zimarino M; Contarini M; Russo F; Calabrò P; Andò G; Varbella F; Garducci S; Palmieri C; Briguori C; Karagiannis A; Valgimigli M Catheter Cardiovasc Interv; 2020 Nov; 96(6):1156-1171. PubMed ID: 31883294 [TBL] [Abstract][Full Text] [Related]